Table 5

TYMS mRNA expression was associated with patient progression free survival
Progression free survival (months)
Total N Events Median HR 95% C.I. Wald’s p
Subgroup A Aberrant TYMS
No taxanes vs. Taxanes 43 vs. 35 32 vs. 31 12.53 vs. 4.00 0.335 0.199-0.565 <0.001
No platinum vs. platinum 66 vs. 13 53 vs. 10 6.72 vs. 16.92 2.247 1.097-4.602 0.027
No tax/plat vs. tax/plat 52 vs. 26 45 vs. 18 4.26 vs 15.64 1.982 1.143-3.437 0.015
Normal TYMS
No taxanes vs. Taxanes 41 vs. 34 32 vs. 29 7.48 vs. 4.39 0.716 0.431-1.190 0.197
No platinum vs. platinum 66 vs. 9 53 vs. 8 6.89 vs. 5.97 0.844 0.400-1.779 0.656
No tax/plat vs. tax/plat 53 vs. 22 43 vs. 18 5.64 vs. 8.56 1.270 0.731-2.205 0.396
Subgroup B Aberrant TYMS
No taxanes vs. Taxanes 51 vs. 36 36 vs. 32 12.53 vs. 3.77 0.349 0.212-0.575 <0.001
No platinum vs. platinum 73 vs. 14 58 vs. 10 6.72 vs. 16.92 2.216 1.088-4.512 0.028
No tax/plat vs. tax/plat 57 vs. 30 48 vs. 20 13.21 vs. 19.31 2.112 1.248-3.573 0.005
Normal TYMS
No taxanes vs. Taxanes 47 vs. 39 36 vs. 33 6.89 vs. 5.93 0.771 0.479-1.242 0.286
No platinum vs. platinum 76 vs. 10 60 vs. 9 7.44 vs. 5.64 0.731 0.362-1.478 0.383
No tax/plat vs. tax/plat 62 vs. 24 49 vs. 20 12.18 vs. 12.85 1.049 0.623-1.767 0.857

Kotoula et al.

Kotoula et al. BMC Cancer 2012 12:342   doi:10.1186/1471-2407-12-342

Open Data